Randomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects With Triple Negative Locally Advanced Non-resectable and/or Metastatic Breast Cancer

NCT00633464 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

79

Enrollment

INDUSTRY

Sponsor class

Conditions

Triple Negative Locally Advanced Non-resectable Breast Cancer
Metastatic Breast Cancer

Interventions

DRUG: ixabepilone
DRUG: ixabepilone + cetuximab

Sponsor

R-Pharm